Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Apple Inc.'s stock has struggled to find positive momentum this year, and analysts at Needham & Company don't see major catalysts ahead that can help put shares on a better course.

Regeneron Pharmaceuticals saw a downgrade from Wells Fargo, slicing its stock rating from "overweight" to "equal weight" and ...

Regeneron Pharmaceuticals REGN +2.20% Get Free Report has outperformed the market over the past 15 years by 9.69% on an ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

The S&P 500 (^GSPC) logged its best May since 1990 and its best month since Nov. 2023, rising over 6%, while the Dow (^DJI) ...

Wall Street absorbed a fresh wave of tariff uncertainty after a federal appeals court reinstated President Trump's global ...

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few ...

UBS Asset Management Americas sharply increased its Regeneron stake by 30.1%, snapping up 226,952 additional shares in Q4.

The slower-than-expected switch to Eylea HD and the regulatory challenges with the pre-filled syringe formulation could further exacerbate this issue ... of Regeneron’s stock value on its ...

Regeneron is buying bankrupt genetic testing firm 23andMe, which helped usher in the era of consumer DNA test kits nearly two ...

Cantor Fitzgerald maintains Regeneron stock with $695 target Open in App Get 45% Off Sign In Free Sign Up ...